Last updated on February 2018

Study of Nab-paclitaxel in Sensitive and Refractory Relapsed SCLC


Brief description of study

Evaluate the activity and safety of Nab-paclitaxel in patients with sensitive or refractory SCLC who relapsed after cisplatin or carboplatin and etoposide first-line chemotherapy.

Detailed Study Description

Phase II study of NAB-paclitaxel in SensiTivE and Refractory relapsed SCLC

Clinical Study Identifier: NCT03219762

Find a site near you

Start Over